DCTH Logo

Delcath Systems, Inc. (DCTH) 

NASDAQ
Market Cap
$310.47M
Sector
Healthcare
Industry
Medical—Specialties
Rank in Sector
149 of 775
Rank in Industry
1 of 2

Largest Insider Buys in Sector

DCTH Stock Price History Chart

DCTH Stock Performance

About Delcath Systems, Inc.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in …

Insider Activity of Delcath Systems, Inc.

Over the last 12 months, insiders at Delcath Systems, Inc. have bought $419,962 and sold $0 worth of Delcath Systems, Inc. stock.

On average, over the past 5 years, insiders at Delcath Systems, Inc. have bought $620,737 and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Vukovic Vojo (Chief Medical Officer) — $360,000. MICHEL GERARD J (Chief Executive Officer) — $199,920. Aharon Gil (director) — $100,001.

The last purchase of 26,882 shares for transaction amount of $100,001 was made by SALAMON STEVEN A J (director) on 2024‑03‑19.

List of Insider Buy and Sell Transactions, Delcath Systems, Inc.

2024-03-19Purchasedirector
26,882
0.106%
$3.72$100,001+86.22%
2024-03-19Purchasedirector
26,882
0.106%
$3.72$100,001+86.22%
2023-12-12PurchaseChief Medical Officer
40,000
0.1728%
$3.00$120,000+82.14%
2023-12-08PurchaseChief Executive Officer
34,000
0.1516%
$2.94$99,960+92.35%
2023-11-17Purchasedirector
100,000
0.6437%
$2.40$240,410+122.22%
2023-11-17PurchaseSVP of Finance, PFO and PAO
30,000
0.1952%
$2.43$72,900+122.22%
2023-11-16PurchaseChief Medical Officer
60,000
0.3928%
$2.48$148,800+118.42%
2023-11-16PurchaseSee Remarks
40,000
0.2618%
$2.48$99,200+118.42%
2023-10-13PurchaseChief Operating Officer
14,505
0.0944%
$3.44$49,897+36.99%
2023-08-21Purchasedirector
10,550
0.093%
$4.80$50,640-11.42%
2023-03-29PurchaseChief Executive Officer
19,646
0.0001%
$4.84$95,087-19.95%
2022-12-14Purchasedirector
15,215
0.1678%
$3.62$55,045+26.22%
2022-12-14Purchasedirector
15,215
0.1678%
$3.62$55,045+26.22%
2022-12-13PurchaseChief Executive Officer
51,725
0.4573%
$2.90$150,003+26.22%
2022-07-20PurchaseChief Executive Officer
62,814
0.6782%
$3.98$250,000+7.50%
2022-05-16PurchaseChief Operating Officer
3,300
0.0396%
$4.61$15,213-13.01%
2022-05-13Purchase
5,000
0.0635%
$5.03$25,135-15.89%
2022-05-12Purchase
6,000
0.0764%
$4.90$29,424-13.19%
2022-04-19Purchase
1,600
0.0191%
$6.25$10,000-36.05%
2022-04-19Purchase
1,600
0.0191%
$6.25$10,000-36.05%

Insider Historical Profitability

<0.0001%
SALAMON STEVEN A Jdirector
1121025
3.5061%
$9.71140<0.0001%
Aharon Gildirector
1069710
3.3456%
$9.7130<0.0001%
MICHEL GERARD JChief Executive Officer
262345
0.8205%
$9.71110<0.0001%
Vukovic VojoChief Medical Officer
100000
0.3128%
$9.7120
Rosalind Advisors, Inc.director
1038828
3.249%
$9.71120<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Aigh Capital Management Llc$11.09M8.492.36M+99.61%+$5.54M6.34
Vivo Capital$7.95M61.67M+94.9%+$3.87M0.69
Bvf Inc Il$5.73M4.331.2M+23.14%+$1.08M0.04
The Vanguard Group$3.26M2.46683,686+30.97%+$771,204.01<0.0001
CIBC World Markets$1.24M0.94260,280-0.44%-$5,482.78<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.